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Abstract This study aimed to identify providers involved in
diagnosing ankylosing spondylitis (AS) following back pain
diagnosis in the USA and to identify factors leading to the
delay in rheumatology referrals. The Truven Health
MarketScan® US Commercial Database was searched for pa-
tients aged 18–64 years with back pain diagnosis in a non-
rheumatology setting followed by AS diagnosis in any setting
during January 2000–December 2012. Patients with a rheu-
matologist visit on or before AS diagnosis were considered
referred. Cox regression was used to determine factors asso-
ciated with referral time after adjusting for age, sex, comor-
bidities, physician specialty, drug therapy, and imaging proce-
dures. Of 3336 patients included, 1244 (37%)were referred to
and diagnosed by rheumatologists; the others were diagnosed
in primary care (25.7 %), chiropractic/physical therapy (7 %),
orthopedic surgery (3.8 %), pain clinic (3.6 %), acute care
(3.4 %), and other (19.2 %) settings. Median time from back
pain diagnosis to rheumatology referral was 307 days and
from first rheumatologist visit to AS diagnosis was 28 days.
Referred patients were more likely to be younger (hazard ratio
[HR] = 0.986; p < 0.0001), male (HR= 1.15; p = 0.0163),
diagnosed with uveitis (HR=1.49; p=0.0050), referred by
primary care physicians (HR=1.96; p<0.0001), prescribed
non-steroidal anti-inflammatory drugs (HR = 1.55;
p < 0.0001), disease-modifying antirheumatic drugs
(HR=1.33; p<0.0001), and tumor necrosis factor inhibitors
(HR=1.40; p=0.0036), and to have had spinal/pelvic X-ray
prior to referral (HR=1.28; p=0.0003). During 2000–2012,
most patients with AS were diagnosed outside of rheumatol-
ogy practices. The delay before referral to rheumatology was
10 months; AS diagnosis generally followed within a month.
Earlier referral of patients with AS signs and symptoms may
lead to more timely diagnosis and appropriate treatment.
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Introduction
The delay between symptom onset and diagnosis of ankylos-
ing spondylitis (AS) has been estimated at approximately 8 to
11 years in Europe [1–3] and approximately 13 years in the
USA [4]. Diagnostic delay in AS has been attributed to the
common occurrence of mechanical back pain in the general
population, the typically insidious onset of the disease, young
age at onset, and a lack of clinical symptoms, signs, or bio-
markers unique to AS [5–7]. AS is associated with consider-
able pain and stiffness, impaired health-related quality of life
(HRQoL), decreased work productivity, and substantial dis-
ability [5, 8]. Nonsteroidal anti-inflammatory drugs (NSAIDs)
and anti-tumor necrosis factor α (anti-TNF) agents are effec-
tive in reducing pain and stiffness and improving physical
function [9, 10] and are recommended in the treatment of
AS [11]. Moreover, these treatments may be more effective
early in the course of disease, when inflammatory processes
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are predominant [6, 7]. Delayed diagnosis and treatment con-
tribute to the considerable physical, psychological, and eco-
nomic burden on AS patients and their caregivers [5].
In the USA, the majority (approximately 60 %) of patients
with low back pain consult with general practitioners, whereas
35–37 and 24–30 % of patients seek care from the orthope-
dists and chiropractors, respectively [12, 13]. However, US
primary care guidelines do not explicitly specify referral to a
rheumatologist in cases of suspected AS [14, 15], and it is
unclear how frequently and accurately patients are diagnosed
within the primary care setting.
Strategies for appropriate and timely referral to rheumatol-
ogists aimed at shortening the diagnostic delay in AS have
been described [6, 7, 16]. These strategies work through im-
proved education of health care providers and recognizing
clues for better identification of possible AS patients.
Because chronic back pain is often the first symptom of AS,
these strategies aim to assist primary care physicians (PCPs) in
distinguishing patients with inflammatory back pain from
those with mechanical or nonspecific back pain and to recog-
nize other typical clinical features of spondyloarthritis.
However, specific factors that influence diagnostic and refer-
ral patterns within the primary care setting remain largely
uncharacterized. To date, no studies have examined the rela-
tionship between diagnostic delay and the type of care re-
ceived by AS patients prior to diagnosis.
The current study sought to identify the health care pro-
viders who make the diagnosis of AS in patients with chronic
back pain in the USA, to assess treatment and referral patterns,
and to identify factors associated with diagnostic delay in a
large sample of patients who initially presented in non-
rheumatology settings including primary care. In particular,
we aimed to describe patterns of prescription drug therapy,
use of diagnostic imaging, and rheumatology referral during
the period from back pain diagnosis to AS diagnosis.
Patients and methods
Study design and patient population
A retrospective, longitudinal cohort study was conducted
using Truven Health MarketScan® US Commercial Claims
Database. Pharmacy and medical claims associated with
127,137,195 patients were assessed for the January 2000–
December 2012 time period. We identified patients aged 18–
64 years who had an initial diagnosis of back pain in a non-
rheumatology setting, followed by ≥1 diagnosis code for AS
(International Statistical Classification of Diseases, Ninth
Revision, Clinical Modification [ICD-9] code = 720.0) in
any clinical setting (rheumatology or non-rheumatology;
Fig. 1). Diagnosis of back pain was based on a set of 38
ICD-9 codes as described by Cherkin and colleagues [17].
The set includes diagnoses of back pain arising from a variety
of non-inflammatory or mechanical etiologies, including
spondylosis, spinal stenosis, spondylolisthesis, lordosis,
sprains and fractures, sciatica, and others (Table S1).
Continuous eligibility for ≥365 days before and after the initial
back pain diagnosis date was required, and patients were
followed continuously until diagnosis of AS (Fig. 1a).
Individuals enrolled in health maintenance organizations were
excluded, as were those with a diagnosis of chronic inflam-
matory diseases (AS, rheumatoid arthritis [RA], psoriasis,
psoriatic arthritis, Crohn’s disease, or ulcerative colitis) on or
before the initial back pain diagnosis date. Patients who had an
initial rheumatologist visit before the back pain diagnosis date
were also excluded. Patients who had an initial rheumatologist
visit after AS diagnosis were excluded from the primary anal-
ysis; however, these patients were assessed for rheumatologist
confirmation of the AS diagnosis. Patients with a rheumatol-
ogist visit on or before AS diagnosis were considered to have
been referred to the rheumatologist for diagnosis (Fig. 1b;
referred cohort); those with no rheumatologist visit were con-
sidered non-referred (Fig. 1b; non-referred cohort). This re-
search was conducted in accordance with the Helsinki
Declaration; exemption from Institutional Review Board re-
view was granted because the study used de-identified data to
protect patient confidentiality.
Study measures
The study assessed the proportion of patients referred to rheu-
matologists for diagnosis of AS, drug prescriptions, and diag-
nostic imaging procedures ordered by non-rheumatologists in
the period from back pain diagnosis to either AS diagnosis
(for non-referred patients) or rheumatologist referral (for re-
ferred patients) and prescribing/referring physician specialty.
The outcome of interest was time to referral, defined as time
from the first non-rheumatologist visit for back pain to the first
rheumatologist visit, at or before the time of AS diagnosis.
This study included time-independent (those that could not
randomly change with time) and time-dependent (those that
could randomly change with time) factors that could influence
the time to rheumatologist referral in AS patients. Age, sex,
and comorbidities as assessed at back pain diagnosis date were
considered time-independent variables. Comorbidities
assessed included diabetes mellitus, cardiovascular disease,
hypertension, renal disease, cancer (any), and uveitis. Time-
dependent variables were captured from index date to AS
diagnosis date and included physician specialty, prescription
drug therapy, and diagnostic imaging procedures carried out.
Physician specialty under which all prescription drug and
health care service claims were provided included primary
care, orthopedic surgery, pain management, chiropractic/
physical therapy, acute care, and Bother^ (which included
any specialties not specified above, as well as instances where
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physician information was missing). Prescription drugs
assessed included NSAIDs, disease-modifying antirheumatic
drug (DMARDs), corticosteroids, opiate pain medications,
and anti-TNF therapy. Diagnostic imaging procedures
assessed included X-rays, magnetic resonance imaging
(MRI), and computed tomography (CT) scans of the spine
and pelvis.
Statistical analysis
Demographic and clinical characteristics, patterns of prescrip-
tion drug use, and diagnostic imaging procedures received
were compared between referred and non-referred patients
using descriptive statistics. A time-dependent Cox proportion-
al hazard model was used to determine factors associated with
time to referral. The model was adjusted for age, sex, comor-
bidities, physician specialty, drug therapy, and imaging proce-
dures; time-dependent variables were adjusted annually in the
model. A stepwise selection method was used to determine
statistically significant predictors of referral time. Hazard ra-
tios with 95 % confidence intervals (CI) were reported. Data
management and analysis was accomplished via PC-SAS®
version 9.2 (SAS Institute Inc., Cary, NC), with an a priori
alpha set at p<0.05.
Results
Sociodemographic characteristics
A total of 3336 patients had an initial diagnosis of back pain in
a non-rheumatology setting, followed by a diagnosis of AS
and met all inclusion criteria. Of these, 1244 (37 %) patients
were referred to rheumatologists for AS diagnosis and the
remaining (n=2092; 63 %) were diagnosed with AS outside
of rheumatology practices (Fig. 1b). Non-referred patients
were most frequently diagnosed in a primary care setting
(25.7 %); others were diagnosed in a chiropractic/physical
therapy (7 %), orthopedic surgery (3.8 %), pain clinic
(3.6 %), acute care (3.4 %), or other (19.2 %) setting
(Fig. 2). An additional 347 patients were initially diagnosed
by a non-rheumatologist but had a rheumatologist visit after
diagnosis (Fig. 1b). Of these, 145 (41.8 %) had their AS di-
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Fig. 1 Study design and patient
selection. An overview of the
study design is shown in panel a.
The follow-up period (i.e., the
period of time from back pain
diagnosis to AS diagnosis) is
outlined in red. Patient flow is
depicted in panel b. Populations
included and excluded from the
main analysis are depicted by the
blue and gray boxes, respectively.
The orange boxes depict a patient
population that was excluded
from the main analysis owing to
primary diagnosis by a non-
rheumatologist but who had their
diagnosis subsequently confirmed
by a rheumatologist. AS =
ankylosing spondylitis; CD =
Crohn’s disease; HMO = health
maintenance organization; PsA =
psoriatic arthritis; PsO =
psoriasis; RA = rheumatoid
arthritis; UC = ulcerative colitis.
aPatients with no interruption in
insurance status
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patients (58.2 %) were diagnosed by the rheumatologist with
other disorders, including joint effusion, unspecified back dis-
order, rheumatoid arthritis, rheumatism not otherwise speci-
fied, osteoarthritis, and spondylosis. In total, 1389 (1244+
145, 41.6 % of total) patients had a rheumatologist-
confirmed diagnosis of AS.
A comparison of demographic and clinical characteristics
between the 1244 referred and 2092 non-referred patients at
the index date is shown in Table 1. Referred patients were
slightly younger than non-referred patients (mean age 43 vs
46 years; p<0.0001); approximately half of patients in each
group were women.
Patterns of prescription drug use and imaging procedures
received by referred and non-referred patients
between back pain diagnosis and AS diagnosis
Patterns of prescription drug use and diagnostic imaging pro-
cedures ordered by non-rheumatology providers in the period
between back pain diagnosis and AS diagnosis (for 2092 non-
referred patients) or rheumatologist referral (for 1244 referred
patients) are summarized in Fig. 3 and Table 2. A majority of
both referred and non-referred patients were prescribed
NSAIDs (64.8 and 53.9 %, respectively) and opiate pain med-
ications (57.5 and 56.3 %, respectively) (Fig. 3a). In contrast,
DMARDs and anti-TNF agents were prescribed less com-
monly by non-rheumatology providers; anti-TNF agents were
prescribed in 127 (10.2 %) of referred and 71 (3.4 %) of non-
referred patients (5.9 % of total). Anti-TNF agents prescribed
by non-rheumatologists were used for both inflammatory and
non-inflammatory disorders diagnosed after the initial back
pain diagnosis date, including RA (26.9 %), back disorder
not specified (18.2 %), spondylosis (18.2 %), rheumatism
not otherwise specified (15.2 %), joint effusion (15.2 %),
and osteoarthritis (9.1 %). Referred patients were more likely
than non-referred patients to receive prescriptions of NSAIDs,
DMARDs, corticosteroids, and anti-TNF agents (p<0.0001
each) prior to AS diagnosis or rheumatologist referral. As
shown in Table 2, PCPs were the primary prescribers for all
medications.
Approximately 75 % (n=2450) of all patients received at
least one diagnostic imaging procedure (X-ray, CT scan, or
MRI) of the spine and/or pelvis in the period between back
pain diagnosis and either AS diagnosis or rheumatologist re-
ferral (Fig. 3b). Significantly greater proportions of referred
patients than non-referred patients received X-rays (71.3 vs
56.5 %; p<0.0001) and MRI (42.3 vs 38.8 %; p=0.0422).
Referred patients were more likely than non-referred patients
to have received imaging procedures specific to the pelvis
(Fig. 3b). Imaging procedures (both pelvic and spinal) were
primarily ordered by PCPs and acute care specialists in both
referred and non-referred patients (Table 2).
Factors associated with the time to rheumatologist referral
The median time from back pain diagnosis to rheumatol-
ogist referral was 307 (interquartile range 81–782) days,
and median time from referral to AS diagnosis was 28
(interquartile range 0–194) days. Factors associated with
referral time are presented in Table 3. Over the study
period, the probability of referral decreased by approxi-
mately 1 % for each year of age, was 15 % greater
among men versus women, and was 49 % greater among
patients with uveitis versus those without uveitis. Other
comorbidities were not significantly associated with re-
ferral time. With the exception of corticosteroids, pre-
scription drug usage during the time from back pain di-
agnosis to AS diagnosis was strongly associated with
referral time; the probability of referral was 55 % greater
among patients who received NSAIDs, 33 % greater
among patients who received DMARDs, 40 % greater
among patients who received anti-TNF therapy, and
18 % lower among patients who received opiates.
Patients who received X-rays (pelvic and/or spinal) dur-
ing the period from back pain diagnosis to AS diagnosis
were 28 % more likely to be referred than those without
X-ray, whereas patients with CT scans (pelvic and/or
spinal) were 29 % less likely to be referred. MRI was
not significantly associated with referral time.
Discussion
This large, retrospective analysis of the administrative
claims data of 127 million individuals over a 10-year pe-
riod provides several unique observations regarding the
diagnosis of AS in the USA. First, of all patients with
an initial diagnosis of back pain who subsequently were
diagnosed with AS, only 37 % were referred to rheuma-






























Fig. 2 Diagnosis of AS by physician specialty. BOthers^ consists of any
provider not specified as rheumatologist, primary care provider (PCP),
chiropractor/physical therapist (PT), orthopedist, pain management, or
acute care specialist or where provider specialty was missing. AS = anky-
losing spondylitis
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rheumatologists. Previous studies have shown that non-
rheumatology providers see most patients with chronic
back pain. For example, an analysis of data from the
National Health and Nutrition Examination Survey
(NHANES 1976–1980) showed that patients with low
back pain most commonly sought care from PCPs (ap-
proximately 60 %), followed by orthopedists (30 %) and
chiropractors (30 %) [12]. Similar results were reported in
a 2006 survey of 2809 patients with back and/or neck
pain in North Carolina [13]. In addition, in a recent sur-
vey of 190 rheumatologists in the USA and Canada, the
majority (95 %) of rheumatologists reported that PCPs
were the main referral source for patients with chronic
back pain beginning before age 45, followed by
physical/occupational therapists (24 %), chiropractors
(18 %), and other specialists (orthopedists, pain manage-
ment specialists, and psychiatrists [28 %]) [18]. Another
recent study suggested that <10 % of patients with AS in
the USA self-refer to rheumatology [4]. It was surprising,
however, that as many as two thirds of patients remained
in the non-rheumatology setting for diagnosis of AS.
Although the basis for the low rate of referral is unclear,
it may be related to the lack of accessibility and/or long
waiting times for rheumatology care as well as a focus on
appropriate surgical referral in US-specific primary care
guidelines with little guidance on when to consider rheu-
matology referral [14, 15, 19–21].
Second, the median delay from back pain diagnosis to
rheumatologist referral was approximately 10 months, but
following consultation with a rheumatologist, patients
were generally diagnosed with AS within 1 month.
Predictors of shorter time to referral included younger
age, male sex, presence of uveitis, increased use of pre-
scription drug therapy, use of X-ray imaging, and PCP as
the referring physician specialty. These results suggest
that referral decisions may be driven both by appropriate
recognition of AS features (young age of onset, uveitis,
and structural damage) and by a continued misperception
among non-rheumatologists that AS is rarely seen in
women [22]. Increased use of prescription drug therapy
was also associated with shorter time to referral, which
may suggest that referred patients had greater disease
Table 1 Patient characteristics at
back pain diagnosis date Characteristic Patients referred to
rheumatologist (n= 1244)
Patients not referred to
rheumatologist (n= 2092)
P valuea
Age, years 42.9 45.8 <0.0001
Female, % 50.7 % 50.0 % 0.7058
Comorbid condition, %
Diabetes mellitus 5.1 % 9.8 % <0.0001
Cardiovascular diseaseb 7.1 % 10.2 % 0.0025
Hypertension 18.4 % 23.5 % 0.0006
Renal disease 0.5 % 1.1 % 0.0492
Cancer (any) 17.3 % 19.0 % 0.2215
Uveitis 4.3 % 3.9 % 0.5805
a Chi-square test
b Includes myocardial infarction, ischemic heart disease, angina, cerebrovascular disease, atherosclerosis, aortic
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Fig. 3 Patterns of prescription drug use (a) and imaging procedures (b)
by referred and non-referred patients. CT = computed tomography;
DMARD = disease-modifying antirheumatic drug;MRI = magnetic reso-
nance imaging; NSAID = non-steroidal anti-inflammatory drug; TNF =
tumor necrosis factor
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activity than non-referred patients. Although PCPs were
more likely than other specialists to refer in a timely man-
ner, our results suggest that better identification and ear-
lier referral would be associated with faster and more
accurate diagnosis, supporting the use of referral strate-
gies in the primary care setting [6].
Third, of patients who were initially diagnosed with AS
by a non-rheumatologist and then referred to a rheumatol-
ogist, only 42 % were confirmed to have AS, and the di-
agnosis was changed in 58 % of the patients—mostly to a
non-inflammatory condition—by the rheumatologists.
Among many other possible reasons, inappropriate use of
imaging modalities by non-rheumatologists may have con-
tributed to misdiagnosis. In particular, only 21 % of non-
referred and 45 % of referred patients received pelvic X-
rays by non-rheumatologists, which are essential for the
diagnosis of AS [23]. MRI of the pelvis was rarely per-
formed in the non-rheumatology setting, though MRI of
the spine was ordered by non-rheumatologists in approxi-
mately one third of both referred and non-referred patients,
h i gh l i g h t i n g an educ a t i o n a l g ap among non -
rheumatologists in the understanding of appropriate imag-
ing tests when considering an AS diagnosis. In addition,
approximately 6 % of the patients were prescribed anti-
TNF agents by non-rheumatologists without confirmation
of an immune-mediated inflammatory disorder. This obser-
vation, combined with the high rate of misdiagnosis of AS,
raises the issue of potential inappropriate use of expensive
and potentially hazardous medications by non-specialists.
Our results are generally consistent with previous studies
showing insufficient awareness of AS in the primary care
setting. In a study of 807 patients with AS in the UK, the mean
diagnostic delay was 8.6 years, yet a majority of patients
(62.1 %) reported consulting a health care practitioner within
1 year of symptom onset. Because most of these patients were
ultimately referred to rheumatologists, the authors suggested
that the diagnostic delay was associated with inadequate rec-
ognition of signs and symptoms by primary care physicians
[21]. In another study of 70 patients with AS in India, incor-
rect initial diagnoses were made in 77 % of patients.
Table 2 Percentage of patients who received prescription drug therapy and imaging procedures as a function of prescribing physician specialty
PCP (%) Orthopedist (%) Pain management (%) Chiropractor/PT (%) Acute care (%) Other/missing (%)
Referred cohorta
Prescription drugs
NSAIDs 46.2 19.0 3.2 4.4 7.8 19.4
DMARDs 47.3 8.3 4.4 5.4 8.3 26.3
Corticosteroids 58.1 13.1 3.7 5.6 5.6 13.8
Opiates 49.4 22.6 6.4 3.8 6.4 11.4
Anti-TNFc 40.0 12.0 1.3 5.3 8.0 33.3
Imaging
X-ray 22.5 12.0 2.6 8.3 22.9 31.7
CT scan 28.4 5.2 3.1 3.9 45.9 13.5
MRI 25.7 13.1 7.4 7.0 28.1 18.6
Non-referred cohortb
Prescription drugs
NSAIDs 55.4 16.6 4.5 5.7 3.1 14.7
DMARDs 65.1 8.1 2.7 3.4 5.4 15.3
Corticosteroids 62.3 12.1 3.6 2.5 5.8 13.7
Opiates 51.9 21.7 6.4 3.6 4.0 12.4
Anti-TNFc 59.5 13.5 0.0 2.7 2.7 21.6
Imaging
X-ray 39.5 17.5 4.6 11.4 14.2 12.8
CT scan 31.0 6.2 6.8 2.5 37.5 16.0
MRI 32.6 10.0 6.7 6.8 25.9 18.0
Analysis includes all patients who received a given therapy or procedure (total of 100 % for each category)
CT computed tomography, DMARDs disease-modifying antirheumatic drugs,MRI magnetic resonance imaging, NSAIDs non-steroidal anti-inflamma-
tory drugs, PT physical therapist, TNF tumor necrosis factor
a For the referred cohort, data represent the year prior to rheumatologist referral
b For the non-referred cohort, data represent the year prior to AS diagnosis
c Anti-TNF use was reported in 5.9 % of the total population
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Misdiagnoses were most frequently ascribed to orthopedists
and primary care physicians, and the authors concluded that
misdiagnosis was the largest contributor to diagnostic delay in
their sample [24].
One of the strengths of our study is the use of a large
administrative claims database, which allowed the assessment
of real-world pharmacy and medical claims in a large, nation-
ally representative population of patients with AS. However, it
contains some limitations inherent to claims analysis. The ac-
curacy of the diagnosis codes used to identify patients included
and excluded from the analysis is unknown; however, we note
that the database used in the current study has been exploited
extensively in previous analyses. In addition, we could not
capture clinical factors such as disease severity and non-
prescription NSAID use. In addition, our study assessed the
time from back pain diagnosis to AS diagnosis, rather than
delay between back pain onset to AS diagnosis. Therefore, it
was not possible to compare our results directly to studies that
determined diagnostic delay relative to symptom onset.
Additionally, patients with chronic back pain who were not
ultimately diagnosed with AS are not included in this dataset
and it is not known how these patients are managed. In addi-
tion, due to limitations in ICD-9 coding, our data set included
both acute and chronic back pain prior to AS diagnosis and also
included patients with diagnoses of back pain arising from a
variety of non-inflammatory or mechanical etiologies, includ-
ing spondylosis, spinal stenosis, spondylolisthesis, lordosis,
sprains and fractures, sciatica, and others (Table S1). By
including a comprehensive panel of back pain diagnoses, our
study captured a large and diverse patient sample, which may
lead to overestimation of study results.
Conclusions
Only one third of patients with AS with a recorded diagnosis
of chronic back pain were referred to rheumatologists before a
diagnosis of AS was made. The median delay from back pain
diagnosis to rheumatologist referral was approximately
10 months, and following consultation with a rheumatologist,
patients were generally diagnosed with AS within 1 month.
Younger age, male gender, presence of uveitis, increased use
of drug therapy and pelvic and/or spinal X-rays, and PCP as
the referring physician were each associated with shorter time
to rheumatology referral. Improved awareness of AS signs
and symptoms in the primary care setting may lead to more
timely and appropriate rheumatology referrals and subse-
quently accurate diagnosis and appropriate treatment.
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